Haruka Ishii

Tokyo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Patient characteristics and treatment efficacy after switching to hypoxia-inducible factor-prolyl hydroxylase inhibitors from erythropoiesis-stimulating agents in non-dialysis-dependent chronic kidney disease patients: the Reach-J CKD cohort study.

Patient characteristics and treatment efficacy after switching to hypoxia-inducible factor-prolyl hydroxylase inhibitors from erythropoiesis-stimulating agents in non-dialysis-dependent chronic kidney disease patients: the Reach-J CKD cohort study.

Journal: BMC nephrology

Published: January 09, 2026

Real-world impact of treatment on growth in children with X-linked hypophosphatemia.

Real-world impact of treatment on growth in children with X-linked hypophosphatemia.

Journal: The Journal of clinical endocrinology and metabolism

Published: November 25, 2025

Health-related quality of life in French adults with X-linked hypophosphatemia: real-world data from the International XLH Registry.

Health-related quality of life in French adults with X-linked hypophosphatemia: real-world data from the International XLH Registry.

Journal: JBMR plus

Published: October 28, 2025

The lived experience of adolescents with X-linked hypophosphataemia treated with burosumab at end of skeletal growth: a mixed-methods analysis.

The lived experience of adolescents with X-linked hypophosphataemia treated with burosumab at end of skeletal growth: a mixed-methods analysis.

Journal: PloS one

Published: September 24, 2025

Adolescents' experience of living with X-linked hypophosphataemia (XLH): a mixed-methods analysis of those who continued and discontinued burosumab treatment after end of skeletal growth.

Adolescents' experience of living with X-linked hypophosphataemia (XLH): a mixed-methods analysis of those who continued and discontinued burosumab treatment after end of skeletal growth.

Journal: Orphanet journal of rare diseases

Published: September 04, 2025

Advancing Patient Evidence in XLH (APEX): Baseline analysis of a global data unification program.

Advancing Patient Evidence in XLH (APEX): Baseline analysis of a global data unification program.

Journal: Bone

Published: June 13, 2025

Health-related quality of life in French pediatric patients with X-linked hypophosphatemia: real-world data from the International XLH Registry.

Health-related quality of life in French pediatric patients with X-linked hypophosphatemia: real-world data from the International XLH Registry.

Journal: JBMR plus

Published: March 07, 2025

The Prevalence and Severity of Pain in Patients With Systemic Sclerosis.

The Prevalence and Severity of Pain in Patients With Systemic Sclerosis.

Journal: The Journal of dermatology

Published: February 06, 2025

Prevalence of Comorbid Hyperparathyroidism and Its Association with Renal Dysfunction in Asian Patients with X-Linked Hypophosphatemic Rickets/Osteomalacia.

Prevalence of Comorbid Hyperparathyroidism and Its Association with Renal Dysfunction in Asian Patients with X-Linked Hypophosphatemic Rickets/Osteomalacia.

Journal: Calcified tissue international

Published: October 17, 2024

Factors Influencing Treatment Satisfaction and Recognition Gaps Between Physicians and Patients with Systemic Sclerosis.

Factors Influencing Treatment Satisfaction and Recognition Gaps Between Physicians and Patients with Systemic Sclerosis.

Journal: Rheumatology and therapy

Published: September 23, 2024

Associations of time-dependent changes in phosphorus levels with cardiovascular diseases in patients undergoing hemodialysis: results from the Japan Dialysis Active Vitamin D (J-DAVID) randomized clinical trial.

Associations of time-dependent changes in phosphorus levels with cardiovascular diseases in patients undergoing hemodialysis: results from the Japan Dialysis Active Vitamin D (J-DAVID) randomized clinical trial.

Journal: Clinical kidney journal

Published: February 12, 2022

Effects of alfacalcidol on cardiovascular outcomes according to alkaline phosphatase levels in the J-DAVID trial.

Effects of alfacalcidol on cardiovascular outcomes according to alkaline phosphatase levels in the J-DAVID trial.

Journal: Scientific reports

Published: January 21, 2022

Showing 1-12 of 15

Last Updated: 09/26/2026